CS
BMY.RT

Credit Suisse’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Credit Suisse’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,866,267
Closed -$10.3M – 4726
2020
Q4 		$10.3M Sell
14,866,267
-6,714,587
-31% -$14.3M 0.01% 1562
2020
Q3 		$48.6M Buy
21,580,854
+1,959,371
+10% +$5.6M 0.03% 619
2020
Q2 		$70.2M Buy
19,621,483
+644,297
+3% +$2.32M 0.05% 397
2020
Q1 		$72.1M Buy
18,977,186
+202,288
+1% +$666K 0.06% 300
2019
Q4 		$56.5M Buy
+18,774,898
New +$48.8M 0.04% 480

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Credit Suisse's BMY.RT Position: Q1 2021 in Review

Credit Suisse sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 14,866,267 shares — an estimated $10.3M sold.

Credit Suisse first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $72.1M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Credit Suisse reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Credit Suisse sold 14,866,267 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $10.3M.
  • Credit Suisse first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Credit Suisse's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $72.1M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.